Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models

BACKGROUND: Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive malignancy with only a 5% 5-year survival rate. Reliable biomarkers for early detection are still lacking. The goals of this study were (a) to identify early humoral responses in genetically engineered mice (GEM) spontaneousl...

Full description

Saved in:
Bibliographic Details
Main Authors: Capello, Michela, Cappello, Paola, Linty, Federica Caterina, Chiarle, Roberto, Sperduti, Isabella, Novarino, Anna, Salacone, Paola, Mandili, Giorgia, Naccarati, Alessio, Sacerdote, Carlotta, Beghelli, Stefania, Bersani, Samantha, Barbi, Stefano, Bassi, Claudio, Scarpa, Aldo, Nisticò, Paola, Giovarelli, Mirella, Vineis, Paolo, Milella, Michele, Novelli, Francesco
Format: Artigo
Language:Inglês
Published: BioMed Central 2013
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3844582/
https://ncbi.nlm.nih.gov/pubmed/24010981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-6-67
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items